ZyVersa Therapeutics annual cash and equivalents
2021
2022
2022
2023
2024
2025
ZyVersa Therapeutics Cash & Equivalents Growth & History (ZVSA)
ZyVersa Therapeutics's cash and equivalents was $101,778 for fiscal 2025.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $101,778 | −$1.4M | −93.35% |
| 2024 | 2024-12-31 | $1.5M | −$1.6M | −51.21% |
| 2023 | 2023-12-31 | $3.1M | — | — |
| 2022 · Dec 31 | 2022-12-31 | $5.9M | $5.0M | +535.75% |
| 2022 · Dec 12 | 2022-12-12 | $699,324 | −$229,065 | −24.67% |
| 2021 | 2021-12-31 | $928,389 | — | — |
ZyVersa Therapeutics quarterly cash and equivalents
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $302,660 | −$1.3M | −81.22% |
| Q4 2025 | 2025-12-31 | $101,778 | −$1.4M | −93.35% |
| Q3 2025 | 2025-09-30 | $527,978 | $405,057 | +329.53% |
| Q2 2025 | 2025-06-30 | $72,086 | −$47,400 | −39.67% |
| Q1 2025 | 2025-03-31 | $1.6M | −$422,044 | −20.75% |
| Q4 2024 | 2024-12-31 | $1.5M | −$1.6M | −51.21% |
| Q3 2024 | 2024-09-30 | $122,921 | −$1.5M | −92.21% |
| Q2 2024 | 2024-06-30 | $119,486 | −$109,207 | −47.75% |
| Q1 2024 | 2024-03-31 | $2.0M | $755,503 | +59.11% |
| Q4 2023 | 2023-12-31 | $3.1M | — | — |
| Q3 2023 | 2023-09-30 | $1.6M | $1.4M | +639.23% |
| Q2 2023 | 2023-06-30 | $228,693 | −$111,346 | −32.75% |
| Q1 2023 | 2023-03-31 | $1.3M | $447,849 | +53.94% |
| Q4 2022 | 2022-12-31 | $5.9M | $5.0M | +535.75% |
| Q4 2022 | 2022-12-12 | $699,324 | −$229,065 | −24.67% |
| Q3 2022 | 2022-09-30 | $213,564 | — | — |
| Q2 2022 | 2022-06-30 | $340,039 | — | — |
| Q1 2022 | 2022-03-31 | $830,224 | — | — |
| Q4 2021 | 2021-12-31 | $928,389 | — | — |
ZyVersa Therapeutics cash and equivalents trends
Between the periods ended 2021-12-31 and 2025-12-31, ZyVersa Therapeutics's cash and equivalents decreased from $928,389 to $101,778, a change of −$826,611. The latest reported quarter, Q1 2026, shows $302,660.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗